echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chinese experts successfully explore single-port robotic lung cancer surgery

    Chinese experts successfully explore single-port robotic lung cancer surgery

    • Last Update: 2021-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Chinese experts successfully explored fewer and more precise single-hole robotic lung cancer surgery
    Chinese experts successfully explored fewer and more accurate single-port robotic lung cancer surgery Chinese experts successfully explored fewer and more precise single-port robotic lung cancer surgery

    China News Service, April 9th ​​(Chen Jing Yao Jun) Robotic surgery is the most cutting-edge technology in minimally invasive thoracic surgery in the world today, which can provide patients with safer, thorough, accurate and fast surgery.


    Currently, clinical robotic chest surgery usually requires 3 or 4 incisions.


    Professor Luo Qingquan’s team proposed a single-hole operation technique of “crossing robotic arms and swapping left and right hands”, effectively avoiding the technical bottleneck of robot “arms” interfering with each other under a single incision, and realizing a single-port-multi-arm robotic chest surgery process , To reduce the trauma to a lower level, and make minimally invasive more "minimally invasive".


    The hospital told reporters that the relevant technical application papers of Professor Luo Qingquan’s team were recently published online in the well-known journal Translational Lung Cancer Research.


    This innovative paper introduces the right lower lobectomy performed by Luo Qingquan’s team using a single-port incision under the "porous robotic system".


    It is understood that in 2009, Professor Luo Qingquan from Shanghai Chest Hospital led the team to complete the robotic lobectomy in China first, opening the application of robotic chest surgery in China.


    During the interview, the reporter learned that at present, the imported robotic surgery systems are basically used in clinical practice by Chinese medical institutions.


    In addition, Professor Luo also took the lead in research topics related to emerging cutting-edge technologies, discussed broadening the indications of robotic surgery, formulated and updated clinical guidelines and expert consensus, and brought more senior patients, young patients, or patients with special comorbidities More and more precise treatment options.


    However, Professor Luo Qingquan said bluntly: "Although we are now promoting minimally invasive surgery, we continue to minimize surgical trauma.


    It is reported that in the future, the Shanghai Thoracic Hospital team will actively explore the application of 5G technology in the remote operation of robotic surgery, and carry out research on difficult robotic features such as locally advanced lung cancer, thymic epithelial tumors, and locally advanced esophageal cancer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.